* Genzyme Transgenics Corp., of Framingham, Mass., reduced itsdebt by $4 million with the sale of 1.3 million shares of commonstock to Genzyme Corp., which now has a 49 percent stake inGenzyme Transgenics.
* MicroGeneSys Inc., of Meriden, Conn., said its influenza vaccine iseffective at inducing protective immune responses, but with fewerside effects than current vaccines. The data came from the first offive Phase I/II clinical trials of the product, which was reported in theJune issue of The Journal of Infectious Diseases.
* Pharmos Corp., of New York, said it completed a Phase I trial inthe U.K. for Dexanabinol (HU-211), which is being developed forstroke, head injury and cardiac arrest.
* StressGen Biotechnologies Inc., of Victoria, British Columbia,closed a Canadian $4.5 million private placement with a syndicate offive venture capital firms.
* The Immune Response Corp., of Carlsbad, Calif., and the SanDiego Regional Cancer Center started a Phase I trial of a coloncancer vaccine, which is comprised of irradiated fibroblasts from askin biopsy, genetically modified to produce interleukin-2, combinedwith irradiated tumor cells excised from the patient.
* Sibia Inc., of La Jolla, said it has extended its three-yearcollaboration with Eli Lilly and Co., of Indianapolis, for another twoyears. Since 1992, the two companies have been conducting researchon neuronal calcium channels, which mediate chemical signalsamong nerve cells, for treatments of disorders, such as Alzheimer'sdisease, stroke and depression. Financial terms were not disclosed.
(c) 1997 American Health Consultants. All rights reserved.